1
00:00:00,360 --> 00:00:04,120
Speaker 1: Now on Bloomberg Radio, we take stock of healthcare. The

2
00:00:04,120 --> 00:00:06,480
Speaker 1: issue of drug pricing has been at the forefront, certainly

3
00:00:06,480 --> 00:00:08,640
Speaker 1: in the political realm for the last few months. We're

4
00:00:08,640 --> 00:00:12,040
Speaker 1: living in a very special time in the history of

5
00:00:12,080 --> 00:00:15,200
Speaker 1: the pharmaceutical industry. Let me three percent of all biotechts

6
00:00:15,200 --> 00:00:17,919
Speaker 1: that start actually get a drug approved. It's a very

7
00:00:17,920 --> 00:00:21,520
Speaker 1: hard thing to do. Bloomberg taking stop healthcare and focus

8
00:00:21,560 --> 00:00:26,640
Speaker 1: on Bloomberg Radio. Yes, healthcare in focus and diabetes in focus.

9
00:00:26,960 --> 00:00:30,560
Speaker 1: Turning our attention now to those people who at some

10
00:00:30,640 --> 00:00:33,280
Speaker 1: point may have to inject themselves up to twenty eight

11
00:00:33,400 --> 00:00:36,480
Speaker 1: times a week with insulin. Here to tell us more

12
00:00:36,520 --> 00:00:39,680
Speaker 1: about some of the alternatives is John Timberlake. He is

13
00:00:39,720 --> 00:00:43,360
Speaker 1: the president and the chief executive of Valeritas, and he

14
00:00:43,479 --> 00:00:45,960
Speaker 1: joins me now. John, thank you very much for being here.

15
00:00:46,040 --> 00:00:48,599
Speaker 1: Thank you, thanks for having me. Well, you know, just

16
00:00:48,680 --> 00:00:51,600
Speaker 1: before we get into the details of some of the

17
00:00:51,720 --> 00:00:55,600
Speaker 1: v GO system, maybe just tell people a little bit

18
00:00:55,640 --> 00:00:58,600
Speaker 1: about your background, because you've been involved in diabetes even

19
00:00:58,640 --> 00:01:03,080
Speaker 1: before you came to Valeritas in two thousand six. That's correct.

20
00:01:03,280 --> 00:01:05,520
Speaker 1: I have spent the last twenty five years focused in

21
00:01:05,560 --> 00:01:08,800
Speaker 1: the air diabetes. I spent fifteen years within the company

22
00:01:08,800 --> 00:01:13,280
Speaker 1: pharmaceutical called Santa Fee responsible for um the diabetes portfolio

23
00:01:13,360 --> 00:01:16,240
Speaker 1: from the phase one up through and on the market.

24
00:01:16,600 --> 00:01:19,280
Speaker 1: And I came to Valaritas ten years ago because I

25
00:01:19,319 --> 00:01:21,960
Speaker 1: saw this technology as something really could net an unmet

26
00:01:21,959 --> 00:01:24,000
Speaker 1: need for the Type two patient with diabetes. All right,

27
00:01:24,080 --> 00:01:27,040
Speaker 1: let's talk about this technology. This is the v GO

28
00:01:27,480 --> 00:01:31,520
Speaker 1: technology and it is wearable on the skin and it's

29
00:01:31,520 --> 00:01:34,000
Speaker 1: just about two inches long. What it actually does it do?

30
00:01:34,800 --> 00:01:38,520
Speaker 1: So the Vego is a very simple, easy to use product.

31
00:01:38,680 --> 00:01:43,800
Speaker 1: It is a wearable patch that is um completely mechanical.

32
00:01:43,880 --> 00:01:46,640
Speaker 1: There's no electronics, there's no batteries. The patient can put

33
00:01:46,640 --> 00:01:48,520
Speaker 1: this on their on their body, leave the house and

34
00:01:48,600 --> 00:01:50,000
Speaker 1: have all the ins and they need for the day.

35
00:01:50,240 --> 00:01:53,000
Speaker 1: So it delivers a constant flow of insulin throughout twenty

36
00:01:53,000 --> 00:01:55,840
Speaker 1: four hours. And then when the patient eats, they can

37
00:01:56,000 --> 00:01:59,600
Speaker 1: very discreetly and easily give themselves additional insulin around meal

38
00:01:59,640 --> 00:02:03,440
Speaker 1: times by simply clicking buttons on the device through their clothing.

39
00:02:03,480 --> 00:02:05,720
Speaker 1: So they could be sitting at a restaurant or the cafeteria.

40
00:02:06,200 --> 00:02:08,480
Speaker 1: And there's a really big social stigma with people taking

41
00:02:08,480 --> 00:02:10,880
Speaker 1: type or Type two is taken insulin in public because

42
00:02:11,200 --> 00:02:14,440
Speaker 1: society has kind of blamed them for having type two diabetes. Well,

43
00:02:14,480 --> 00:02:16,200
Speaker 1: tell people a little bit more about it, like what

44
00:02:16,360 --> 00:02:19,040
Speaker 1: is it that causes type two diabetes and what is

45
00:02:19,080 --> 00:02:22,600
Speaker 1: the addressable market. So diabetes, type two diabetes is really

46
00:02:22,639 --> 00:02:25,960
Speaker 1: as a multi factory disease. It's both the combination the

47
00:02:25,960 --> 00:02:28,760
Speaker 1: body not using the instant the body can make and

48
00:02:28,800 --> 00:02:32,040
Speaker 1: the body not making enough insulin. So it's a very large,

49
00:02:32,600 --> 00:02:35,839
Speaker 1: unfortunate opportunity because there's so many people who have type

50
00:02:35,840 --> 00:02:38,320
Speaker 1: two diabetes. In the United States alone, there were twenty

51
00:02:38,360 --> 00:02:41,120
Speaker 1: two million people who have diabetes, six million of them

52
00:02:41,120 --> 00:02:45,120
Speaker 1: are type twos. Are taking insulint through injections of these

53
00:02:45,120 --> 00:02:47,920
Speaker 1: patients do not reach the reach their seem to control.

54
00:02:48,600 --> 00:02:50,400
Speaker 1: And so that's a huge unmet need of more and

55
00:02:50,480 --> 00:02:52,560
Speaker 1: happening in patients who could benefit from a product like

56
00:02:52,600 --> 00:02:56,840
Speaker 1: the Vego. The Food and Drug Administration has given approval

57
00:02:57,000 --> 00:03:00,239
Speaker 1: for Vigo. Correct, that's correct. The Vego is commercial rights.

58
00:03:00,280 --> 00:03:02,639
Speaker 1: It's it's the only product approved by the FDA that

59
00:03:02,680 --> 00:03:04,960
Speaker 1: has a mechanical delivery of incident for both background and

60
00:03:04,960 --> 00:03:08,040
Speaker 1: meal time insulin. It's also approved by the European Committee.

61
00:03:08,480 --> 00:03:12,679
Speaker 1: And what kind of efficacy. Have you found in UH

62
00:03:12,720 --> 00:03:16,639
Speaker 1: in patients that use this versus let's say, injectable insulin.

63
00:03:16,919 --> 00:03:21,320
Speaker 1: We've demonstrated quite a breath of clinical studies showing the

64
00:03:21,360 --> 00:03:23,520
Speaker 1: patients who are taking injectable insulin when they go to

65
00:03:23,520 --> 00:03:26,680
Speaker 1: the vego, they significally lower their glucose. They do that

66
00:03:26,680 --> 00:03:29,520
Speaker 1: with less prescribed insulin, so that allows them to actually

67
00:03:29,560 --> 00:03:32,040
Speaker 1: get better results using less insulin and actually saving the

68
00:03:32,080 --> 00:03:35,400
Speaker 1: payer system money because of that. Um it's very interesting.

69
00:03:35,440 --> 00:03:38,480
Speaker 1: Of those six million people who take insulin, A large

70
00:03:38,480 --> 00:03:41,600
Speaker 1: study asked these patients who are prescribed meal time insulin

71
00:03:41,600 --> 00:03:43,680
Speaker 1: and sevy two percent said they never take ins and

72
00:03:43,680 --> 00:03:46,640
Speaker 1: out of the house, So it's a huge problem for

73
00:03:46,720 --> 00:03:49,400
Speaker 1: these patients. By wearing the vego underneath their clothing and

74
00:03:49,440 --> 00:03:52,120
Speaker 1: simply being able to click buttons when they eat gives

75
00:03:52,120 --> 00:03:55,000
Speaker 1: them the ability to control their diabetes better. What about

76
00:03:55,040 --> 00:03:57,960
Speaker 1: the cost of vigo their beauty. The good thing about

77
00:03:57,960 --> 00:04:01,280
Speaker 1: the vego is this is a single use, fullly disposable product,

78
00:04:01,480 --> 00:04:04,000
Speaker 1: so it's not classified as a durable medical equipment, which

79
00:04:04,080 --> 00:04:08,360
Speaker 1: is very very important for the reimbursement. Therefore, it's actually reimbursed,

80
00:04:08,440 --> 00:04:11,320
Speaker 1: distributed and fulfilled more like a drug at the pharmacy.

81
00:04:11,720 --> 00:04:14,760
Speaker 1: Ninety five percent of our product was fulfilled the pharmacy. Therefore,

82
00:04:14,800 --> 00:04:17,080
Speaker 1: those patients go to the pharmacy with the prescription and

83
00:04:17,080 --> 00:04:19,919
Speaker 1: they pay a monthly co pay. There's no large deductibles

84
00:04:19,920 --> 00:04:22,320
Speaker 1: and co insurance like there is with durable equipment and

85
00:04:22,400 --> 00:04:26,160
Speaker 1: durable insulin pumps. A couple of questions, so about the company,

86
00:04:26,200 --> 00:04:29,440
Speaker 1: I know you did an alternative initial public offering, I

87
00:04:29,480 --> 00:04:33,520
Speaker 1: believe back in May correct. What is an alternative public

88
00:04:33,560 --> 00:04:36,120
Speaker 1: offering and why did you go that route? So essentially,

89
00:04:36,160 --> 00:04:39,359
Speaker 1: an alternative public offering is essentially a company merging in

90
00:04:39,400 --> 00:04:42,840
Speaker 1: with an already public company and then taking over and

91
00:04:42,960 --> 00:04:45,200
Speaker 1: using that company as a public company. So you're right,

92
00:04:45,400 --> 00:04:47,560
Speaker 1: Laritas now is a public company. We are traded with

93
00:04:47,600 --> 00:04:49,919
Speaker 1: the chicker v l r X, and we did that

94
00:04:50,040 --> 00:04:52,560
Speaker 1: because we're a company now that's at a commercial stage.

95
00:04:52,680 --> 00:04:55,600
Speaker 1: We're an execution stage. We have regatory approval in the

96
00:04:55,680 --> 00:04:59,240
Speaker 1: US and in um Europe. We are producing this at

97
00:04:59,279 --> 00:05:02,000
Speaker 1: commercial scale. All we have a large clerical, steady data

98
00:05:02,000 --> 00:05:04,720
Speaker 1: that's been published, and we have good reimbursement. So really

99
00:05:04,720 --> 00:05:07,000
Speaker 1: it's the right time to access the public markets to

100
00:05:07,000 --> 00:05:10,000
Speaker 1: help support the growth of the company, And what about distribution.

101
00:05:10,080 --> 00:05:12,040
Speaker 1: Who's you have a partner or you're doing that. We

102
00:05:12,120 --> 00:05:14,440
Speaker 1: do know we're actually doing this ourselves today yet. But

103
00:05:14,480 --> 00:05:17,440
Speaker 1: because the product is distributed through the pharmacy channel, we

104
00:05:17,520 --> 00:05:19,719
Speaker 1: basically can provide that product to any pharmacy in the

105
00:05:19,760 --> 00:05:22,560
Speaker 1: country through the wholesalers. I want to thank you very

106
00:05:22,640 --> 00:05:25,800
Speaker 1: much for coming in and sharing this information with us, right,

107
00:05:25,880 --> 00:05:28,600
Speaker 1: Thank you very much. John Timberlake is the president and

108
00:05:28,800 --> 00:05:34,240
Speaker 1: the chief executive of Valeritas talking about a new wearable device.

109
00:05:34,320 --> 00:05:37,799
Speaker 1: It's called Vigo. You wear it on the skin under clothing.

110
00:05:37,800 --> 00:05:41,360
Speaker 1: It's about two inches long, and it fills you with

111
00:05:41,480 --> 00:05:44,640
Speaker 1: the insulin that you need all day long. This is

112
00:05:44,680 --> 00:05:48,360
Speaker 1: taking Stock. I'm pim Fox, and this is Bloomberg.